Weight gain on Ozempic at week 4: what's actually happening

What did @miss_shelf actually say?

Not a lot, technically. The transcript is mostly metaphor: "I understood the assignment. Did the assignment understood who they were assigning the assignment to?" Paired with hashtags like #weightgained and #sosad, the meaning is pretty clear, though. She's four weeks into semaglutide and the scale went up, not down. She thinks Ozempic "didn't do any research" on her specifically. That's the claim we're working with.

To be fair, she never said anything medically irresponsible. She's expressing frustration, not dispensing medical advice. But her implicit suggestion, that Ozempic simply doesn't work for her at week four, deserves a closer look because it's a conclusion a lot of people jump to way too early.

Does the science back this up?

Weight gain in the first few weeks of semaglutide is not rare, and it is not evidence the drug isn't working. That's the short answer. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed average weight loss of 14.9% over 68 weeks, but that's a long-run number. Early weeks are messy. Some participants retained water, others experienced constipation that temporarily added scale weight, and dose titration means therapeutic levels aren't even reached in week four for most protocols.

A 2022 analysis in Obesity Reviews (Rubino et al.) noted that GLP-1 receptor agonists require dose escalation periods of eight to sixteen weeks before patients hit maintenance dosing. Week four is often still the lowest starting dose. Expecting significant fat loss at that stage is like judging a movie by its first thirty seconds.

What did they get wrong, or right?

She got the frustration right. Early weight fluctuations are genuinely confusing, and the marketing around GLP-1 drugs sets up unrealistic timelines. She got the conclusion wrong, or at least premature. "I don't think they did any research" implies the drug is mismatched to her biology at week four. That's not a timeframe that tells you much.

Common reasons for early-stage weight gain on semaglutide include: water retention from dietary changes, constipation (GLP-1 drugs slow gastric emptying, which can add two to four pounds of stool weight), sub-therapeutic dosing during titration, and increased cortisol from the stress of starting a new regimen. None of these mean the drug isn't working. They mean week four is not a verdict.

• Water retention can add two to five pounds in early weeks
• Constipation is reported in roughly 24% of semaglutide users in clinical trials
• Most protocols don't reach maintenance dose until weeks eight to twelve

What should you actually know?

If you're on a GLP-1 and the scale is up at week four, talk to your prescriber before drawing conclusions. The clinical window for evaluating whether semaglutide is working is typically twelve to sixteen weeks at a stable dose, not four weeks into titration. Davies et al. (2021, Lancet Diabetes and Endocrinology) found meaningful weight loss differentiation from placebo only became consistent after week twelve.

Also worth knowing: about ten to fifteen percent of people are considered low responders to semaglutide, based on data from the STEP trials. That's a real phenomenon. But you can't identify yourself as one at week four. You need adequate dose exposure first. If your provider hasn't discussed what "adequate response" looks like at your specific dose and timeline, that's the conversation to have, not a TikTok conclusion.